

## 2023 update on Italian guidelines for the treatment of type 2 diabetes

	CVD(-) HF(-) CKD(-)	CVD(-) HF(-) CKD(+)	CVD(+) HF(-) CKD(-)	CVD(-) HF(+) CKD(-)
	No cardiovascular event, no heart failure, and eGFR ≥ 60 ml/min	No cardiovascular event, no heart failure, and eGFR < 60 ml/min	Previous cardiovascular event, no heart failure,	Heart failure
first-line	Metformin	Metformin <sup>1</sup> SGLT2i	Met. GLP1RA SGLT-2i	SGLT2i
second-line	SGLT2i GLP1RA	GLP1RA		Met. <sup>2</sup> GLP1RA
third-line	DPP4i Acar. Pio. Ins.	DPP4i Acar. Pio. Ins.	DPP4i Acar. Pio. Ins.	DPP4i <sup>3</sup> Acar. Insulin
deprescription	SU剤とグリニドは糖尿病治療に勧められない			

Acta Diabetologica (2023)

We recommend the use of **metformin** as a first-line long-term treatment in patients with type 2 diabetes without previous cardiovascular events and chronic renal failure. **SGLT-2 inhibitors or GLP-1 receptor agonists** are recommended as second-line treatments. **Pioglitazone, DPP-4 inhibitors, acarbose, and insulin** should be considered as third-line treatments. **Sulfonylureas and glinides should not be recommended for the treatment of type 2 diabetes**